

OncoMed Pharmaceuticals, Inc. [OMED] to Ring The NASDAQ Stock Market Closing Bell

ADVISORY, Feb. 7, 2014 (GLOBE NEWSWIRE) --

What:

OncoMed Pharmaceuticals, Inc. [OMED], a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will visit the NASDAQ MarketSite in Times Square.

In honor of the occasion, **Paul J. Hastings, Chairman & CEO**, will ring the Closing Bell.

Where:

NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

When:

Monday, February 10, 2014 - 3:45 p.m. to 4:00 p.m. ET

Contact:

Shari Annes
(650) 888-0902
Shari.annes@oncomed.com

NASDAQ MarketSite:

Christine Barna
(646) 441-5310
Christine.Barna@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: <http://www.facebook.com/NASDAQ>.

For photos from ceremonies and events visit our Instagram Page: <http://instagram.com/nasdaq>

For news tweets, please visit our Twitter page at: <http://twitter.com/nasdaqomx>

For exciting viral content and ceremony photos visit our Tumblr Page: <http://nasdaq.tumblr.com/>

Webcast:

A LiveStream of the NASDAQ Closing Bell will be available at: <https://new.livestream.com/nasdaq/live>

Or

<http://www.nasdaq.com/about/marketsitetowervideo.aspx>

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About OncoMed Pharmaceuticals, Inc. [OMED]:

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSC). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (Anti-DLL4, OMP-21M18), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1), vantictumab (Anti-Fzd7, OMP-18R5), and OMP-54F28 (Fzd8-Fc), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development, Anti-DLL4/Anti-VEGF bispecific and Anti-RSPO3, with Investigational New Drug filings planned for late 2014 or early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.

About NASDAQ OMX Group:

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and approximately 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,300 listed companies with a market value of over \$7 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

-NDAQ-



Source: The NASDAQ OMX Group, Inc.

News Provided by Acquire Media